Research Article

Concomitant Intake of Quercetin with a Grain-Based Diet Acutely Lowers Postprandial Plasma Glucose and Lipid Concentrations in Pigs

Silvia Wein and Siegfried Wolffram

Institute of Animal Nutrition and Physiology, Christian-Albrechts-University of Kiel, Hermann-Rodewald-Straße 9, 24118 Kiel, Germany

Correspondence should be addressed to Silvia Wein; wein@aninut.uni-kiel.de

Received 5 February 2014; Accepted 31 March 2014; Published 16 April 2014

Academic Editor: Ajit S. Narang

Copyright © 2014 S. Wein and S. Wolffram. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Treatment goals of diabetes mellitus type 2 (DMT2) include glycemic control and reduction of nonglycemic risk factors, for example, dyslipidemia. Quercetin, a plant-derived polyphenol, often discussed for possible antidiabetic effects, was investigated for acute postprandial glucose- and lipid-lowering effects in healthy growing pigs. Male pigs (n = 16, body weight = BW 25–30 kg) were fed flavonoid-poor grain-based meals without (GBM) or with quercetin (GBMQ). In a first experiment, postprandial plasma concentrations of glucose, nonesterified fatty acids (NEFA), and triacylglycerols were analyzed in 8 pigs receiving 500 g of either GBM or GBMQ (10 mg/kg BW) in a cross-over design. Blood samples were collected before, and up to 5 h every 30 min, as well as 6 and 8 h after the feeding. In the second experiment, 2 h after ingestions of 1000 g of either GBM or GBMQ (50 mg/kg BW) animals were sacrificed; gastric content was collected and analyzed for dry matter content. Quercetin ingestion reduced postprandial glucose, NEFA, and TG concentration, but two hours after ingestion of the meal no effect on gastric emptying was observed. Our results point to inhibitory effects of quercetin on nutrient absorption, which appear not to be attributable to delayed gastric emptying.

1. Introduction

Diabetes mellitus type 2 (DMT2) is a chronic disease, characterized by peripheral insulin resistance and hyperglycemia [1]. The incidence of DMT2 has increased dramatically in the last decades, and for the year 2030 a worldwide increase up to 370 million diabetic individuals is estimated [2]. Treatment goals of DMT2 include adequate glycemic control and reduction of nonglycemic risk factors such as dyslipidemia [3].

Postprandial dyslipidemia is complex and involves, aside from disturbed fatty acid metabolism, a variety of factors including hyperinsulinemia, insulin resistance, and hyperglycemia [4]. Insulin resistance can cause postprandial dyslipidemia by increasing the enterocytic production of chylomicrons and by an impaired clearance capacity [4]. Postprandial dyslipidemia in turn seems to enhance endothelial dysfunction, oxidative stress, and inflammation [5]. High concentrations of nonesterified fatty acids (NEFA) inhibit insulin-dependent skeletal glucose uptake and insulin-mediated suppression of hepatic gluconeogenesis [6]. Thus, therapeutic strategies target postprandial dyslipidemia [7] as well as postprandial glucose response to improve overall glycemic control [8].

In addition to synthetic pharmaceuticals, the use of plants or plant extracts for the prevention and treatment of diseases has greatly increased [9]. In recent years, biological effects of flavonoids have been intensively investigated. With respect to energy metabolism and the sequel of metabolic disturbances eventually leading to insulin resistance and DMT2, quercetin was found to inhibit the intestinal glucose transport via glucose transporter 2 (GLUT 2) [10], to improve glucose uptake in adipocytes [11], to inhibit adipocyte differentiation...
2. Materials and Methods

2.1. Chemicals. Quercetin (>98%) was obtained from Roth, Karlsruhe, Germany. All chemicals and solvents for high-performance liquid chromatography (HPLC) analysis were obtained from Across Organics Geel, Belgium, and were of HPLC grade.

Plasma TG, NEFA, and glucose were quantified spectrophotometrically using commercially available kits (TG and glucose: Thermo Clinical Labsystems, Vantaa, Finland, and FFA: Randox, Crumlin, UK).

2.2. Animals. All animal experiments were approved by Ministry of Agriculture, Environment and Rural Areas of Land Schleswig-Holstein, Germany, number V312-72241.121-25 (81-7/06). Pigs (n = 16, cross-bred, male, castrated pigs obtained from the Institute of Animal Breeding of the University of Kiel, body weight 25–30 kg) were surgically equipped with indwelling catheters (Cook Deutschland GmbH) placed into the jugular vein. They were fed 500 g of a commercial diet or the grain-based meal supplemented with quercetin (10 mg/kg body weight) in a cross-over design. Wash-out period between treatments was two days. On the days of the experiment, 12 h after their last meal, quercetin was mixed into the normal morning meal and fed immediately. Ingestion of these meals was completed within 3 minutes and water was freely available by nipple drinkers.

2.2.1. Postprandial Nutrient Absorption. To investigate the impact of quercetin on postprandial plasma concentrations of glucose, NEFA, and TG, 8 pigs received either the grain-based meal or the grain-based meal supplemented with quercetin (10 mg/kg body weight) in a cross-over design. Wash-out period between treatments was two days. On the days of the experiment, 12 h after their last meal, quercetin was mixed into the regular morning meal and fed immediately. Ingestion of these meals was completed within 3 minutes and water was freely available by nipple drinkers during the experiment. Blood samples were collected in the 12 h fasted state, and up to 5 h every 30 min, as well as 6 and 8 h after administration. Samples were drawn into heparinized blood containers and immediately centrifuged (1500 × g, 10 min, 4° C). The plasma samples were stored at −80° C until analysis.

2.2.2. Gastric Emptying. Gastric emptying was investigated in 8 pigs which were randomly assigned to one of two groups. Four pigs received either the grain-based meal (1000 g) or the grain-based meal supplemented with quercetin (50 mg/kg BW). On the day of the experiment, 12 h after their last meal, diet was mixed with water (1:2.5, w/v) 15 min before feeding. Thereafter quercetin was mixed into the meal of four animals and meals were immediately fed. Ingestion of these meals was completed within 10 min and blood samples were collected after 2 hours. After the blood sampling, animals were euthanized by injection of pentobarbital (0.3 mL/kg body weight release, WDT, Garbsen, Germany) into the jugular vein. Subsequently, stomachs were ligated at the gastroesophageal and pyloroduodenal junctions and removed from the bodies. Gastric content was completely removed, weighed, and analyzed for dry matter content according to Naumann et al. [13]. Blood samples were analyzed for total flavonol concentrations (quercetin + kaempferol + isorhamnetin + tamarixetin).

2.2.3. High-Performance Liquid Chromatography Analysis of Flavonols. Flavonols were extracted from plasma according to Kumazawa et al. [12], and high-performance liquid chromatography analysis of flavonols was performed as described previously [5]. Shortly, an aliquot (980 mL) of the plasma sample was spiked with 20 mL of rhamnetin (internal standard, 1 mg/20 mL in methanol), acidified (pH 5) with 130 mL of acetic acid (0.583 mol/L), and subsequently treated with 75 mL of a mixture of b-glucuronidase and sulfatase (Sigma-Aldrich Chemie GmbH, Hamburg, Germany; type H-1, final activities: 7300 and 130 U/mL glucuronidase and sulfatase, resp.). After incubation for 1 h at 37° C, 3 mL of acetone was added, and the sample was centrifuged at 4° C at 3700 × g for 45 minutes. The supernatant was evaporated until dryness (partial vacuum at 45° C, SPD2010 SpeedVac System, Thermo Fisher Scientific GmbH, Dreieich, Germany). Residues were resolved in 200 mL of methanol, 77.5 mL of nanopure H2O, and 22.5 mL of HCl (10 mol/L). Thirty microliters of the final solution was injected by a cooled (4° C) autosampler (Jasco, Groß-Umstadt, Germany) onto a C-18 Kromasil 100 column (Jasco, Groß-Q6 Umstadt, Germany) (250 × 4 mm, particle size 5 mm) guarded by a C-18 Inertsil ODS-2 precolumn (Jasco, Groß-Q6 Umstadt, Germany) placed in a column oven at 30° C. The eluent (fluor rate 1 mL/min) was composed of 0.025 mol/L NaH2PO4, pH 2.4, acetonitrile, and methanol (68:27:5 v/v/v). For postcolumn derivatization, the effluent was mixed with Al(NO3)3 (1 mmol/L in methanol containing 75% [v/v] acetic acid) (fluor rate 0.4 mL/min) in a postcolumn reactor. The fluorescence of the flavonol/aluminum complex was measured using a fluorescence detector (excitation wavelength: 422 nm, emission wavelength: 485 nm; FP920, Jasco). Detection limits for quercetin, isorhamnetin, and tamarixetin were 5–7 nmol/L. Interanalysis and interday variances were within 5%. Standards were prepared with pure flavonols (Carl Roth GmbH, Karlsruhe, Germany) and treated like samples. Identification of peaks obtained in plasma samples was performed using the retention times of the pure flavonols (standards).

2.3. Statistical Analysis. For calculations of area under the plasma concentration-time curves (AUC) the linear trapezoidal rule was used (AUC0→∞). Data are presented as group means ± standard deviation (SD). Statistical analysis was performed using two-tailed paired t-test; level for significance was set, P < 0.05. All calculations were performed
Figure 1: Effect of quercetin on postprandial concentrations of glucose, triacylglycerol, and nonesterified fatty acids. Area under the postprandial plasma concentration-time curves of glucose (a), triacylglycerol (b), and nonesterified fatty acids (c) after overnight (12 h) fasting followed by the ingestion of 500 g of a grain-based meal without (clear symbols) or with (filled symbols) the addition of quercetin (10 mg/kg body weight). Data are means (SD); paired, two-tailed t-test (n = 8), significant differences: * indicates P = 0.01 and ** indicates P = 0.0026. AUC: area under the plasma concentration-time curve; NEFA: nonesterified fatty acids; TG: triacylglycerol.

using GraphPad Prism (GraphPad Software Inc., Version 4.01, 2004, San Diego, USA).

3. Results and Discussion

3.1. Results

3.1.1. Body Weight of Pigs Did not Differ at No Time between the Treatment Groups

Postprandial Nutrient Absorption. Fasted plasma glucose, triacylglycerol, and NEFA concentrations were not different between animals (Table 1) at both days of experiments. The postprandial glucose concentrations were lower when the grain-based meal was ingested concomitantly with quercetin (10 mg/kg body weight) as described by lower AUC (Figure 1(a)). Additionally we observed a reduction in postprandial plasma TG and NEFA concentrations when quercetin was ingested with the meal (Figures 1(b) and 1(c)).

Table 1: Fasted (12 h) plasma concentrations of glucose, triacylglycerol, and nonesterified fatty acids in pigs (n = 8).

| Group          | Glucose [mmol/L] | Triacylglycerol [mmol/L] | NEFA [mmol/L] |
|----------------|------------------|--------------------------|---------------|
| Meal           | 4.7 ± 0.5        | 0.38 ± 0.1               | 0.13 ± 0.06   |
| Meal + quercetin | 4.7 ± 0.6       | 0.36 ± 0.1               | 0.15 ± 0.09   |

Gastric Emptying. At 2 h after ingestion of a grain-based meal with or without the addition of quercetin (50 mg/kg body weight) quercetin was detected (3.9 ± 0.3 nmol/mL) only in plasma of pigs fed with quercetin (Figure 2). The gastric emptying, however, was not affected by the ingestion of quercetin (Figure 3).
3.2. Discussion. Flavonoids, which are widely distributed in higher plants, have long been recognized for health promoting effects [14]. Although epidemiological studies point to an association between flavonoid intake and a reduced risk for certain chronic diseases including DMT2 [15], there is not much concise data on in vivo efficacy for many preparations [16–19]. Major challenges in evaluating the systemic bioactivity of flavonoids are due to differences deriving from the fate of flavonoids within the gastrointestinal tract such as sugar moiety, vehicle of application, food matrix effects, and the species-specific metabolism [20]. After ingestion, quercetin is subjected to first-pass metabolism in enterocytes of the small intestine and the liver (conjugation reactions including sulfation, glucuronidation, and methylation) [19] resulting in species-specific metabolites. Thus nonconjugated quercetin is virtually absent in rats [21], pigs [22], and humans [23], rather low in dogs (16% of metabolites with intact flavonol structure) [24], and comparably high in horses (47% of metabolites with intact flavonol structure) [25]. Although in humans, rats, and pigs glucuronidation is considered to be the major conjugation pathway, the conjugation patterns differ. While in pigs and humans only 20–40% of total flavonols occur in methylated form, this fraction is the major metabolite (70%) found in rats [23, 24]. Thus, to draw conclusions from a model organism to human metabolism, the pig seems to be particularly suitable to investigate effects of quercetin. However, aside from systemic bioactivity, local intestinal effects of quercetin seem feasible [26].

The present study clearly shows that quercetin (10 mg/kg body weight) ingested at a low dose concomitantly with a grain-based meal reduced postprandial glucose plasma concentrations. The reduction in postprandial glucose concentration documented in this study is in line with a study where quercetin significantly decreased incremental plasma glucose after a single oral dose of starch and the area under the postprandial glucose response compared with the control group in streptozotocin-induced diabetic rats [27]. Although the present study did not examine intestinal glucose transport, mechanisms responsible for this effect are quite likely through α-glucosidase (EC 3.2.1.20) inhibition. In vitro, quercetin was shown to be a potent inhibitor of α-glucosidase [28] which was even more potent than acarbose, an α-glucosidase inhibitor extensively investigated and widely prescribed antidiabetic drug [29]. Inhibition of intestinal GLUT 2 is also conceivable [10]; either at the basolateral membrane of the enterocyte after passive diffusion of quercetin or luminal at the apical membrane of the enterocyte where GLUT 2 is transiently inserted during a meal [30]. Inhibition of the sodium-dependent glucose transporter 1 (SGLT1) by quercetin aglycone, however, can largely be ruled out [10, 31, 32]. Thus, quercetin aglycone might act as a potent luminal inhibitor of glucose absorption independent of its own transport.

However, aside from inhibited intestinal glucose uptake, lower postprandial glucose concentrations might have resulted from delayed gastric emptying. A study in mice indicated that the intraperitoneal injection of quercetin-rich extracts (30 and 100 mg/kg body weight) inhibited gastric emptying dose dependently [33]. In the present study, the concomitant ingestion of quercetin with a grain-based diet (50 mg/kg body weight) had no effect on gastric emptying at two hours after ingestion, a time point at which quercetin was already present in circulation.

With respect to its antidiabetic properties, quercetin might be even superior to sole α-glucosidase inhibitors.
While they are known to effectively control postprandial glyceremia [34–38], lipid-lowering effects are discussed controversially. Some authors report lipid-lowering activities [34, 36], whereas others found no such effects [35, 37, 38]. Quercetin has previously been shown to have lipid-lowering effects in rats [39, 40], pigs [41], and humans [42] when fed chronically. However, the present study reveals that quercetin exerts also acute lipid-lowering effects such as reduced postprandial plasma TG and NEFA concentrations. Although we cannot determine the underlying mechanisms for these effects from the present study, it can be speculated that the inhibition of pancreatic lipase, the major enzyme responsible for dietary triglyceride digestion, may be included [43].

4. Conclusions

This study emphasizes glucose-lowering effects of quercetin after ingestion of a grain-based meal, which are less clear or even invisible when tested within a glucose challenge. In this context the observed effects of quercetin appear not to be attributable to delayed gastric emptying. Thus, quercetin ingestion might be suitable to acutely assist postprandial glucose and lipid control.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank Wiebke Kühl and Petra Schulz for the excellent technical assistance.

References

[1] T. L. S. Visscher and J. C. Seidell, “The public health impact of obesity,” Annual Review of Public Health, vol. 22, pp. 355–375, 2001.
[2] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004.
[3] “Standards of medical care in diabetes—2008,” Diabetes Care, vol. 31, supplement 1, pp. S12–S54, 2008.
[4] J. Pang, D. C. Chan, P. H. R. Barrett, and G. F. Watts, “Postprandial dyslipidemia and diabetes: mechanistic and therapeutic aspects,” Current Opinion in Lipidology, vol. 23, pp. 303–309, 2012.
[5] S. Pastromas, A.-B. Terzi, D. Tousoulis, and S. Kouloris, “Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus,” International Journal of Cardiology, vol. 126, no. 1, pp. 3–12, 2008.
[6] G. Boden and M. Laakso, “Lipids and glucose in type 2 diabetes: what is the cause and effect?” Diabetes Care, vol. 27, no. 9, pp. 2253–2259, 2004.
[7] J. M. Miles, D. Wooldridge, W. J. Grellner et al., “Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy,” Diabetes, vol. 52, no. 3, pp. 675–681, 2003.
[8] J. Tibaldi, “Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes,” Southern Medical Journal, vol. 102, no. 1, pp. 60–66, 2009.
[9] L. Vargas-Murga, A. Garcia-Alvarez, B. Roman-Vivas et al., “Plant food supplement (PFS) market structure in EC Member States, methods and techniques for the assessment of individual PFS intake,” Food and Function, vol. 2, no. 12, pp. 731–739, 2011.
[10] O. Kwon, P. Eck, S. Chen et al., “Inhibition of the intestinal glucose transporter GLUT2 by flavonoids,” FASEB Journal, vol. 21, no. 2, pp. 366–377, 2007.
[11] X.-K. Fang, J. Gao, and D.-N. Zhu, “Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-LI cells without adipogenesis activity,” Life Sciences, vol. 82, no. 11-12, pp. 615–622, 2008.
[12] Y. Kumazawa, K. Kawaguchi, and H. Takimoto, “Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor α,” Current Pharmaceutical Design, vol. 12, no. 32, pp. 4271–4279, 2006.
[13] C. Naumann, R. Bassler, and R. B. C. Seibold, “Die chemische Untersuchung von Futtermitteln,” in Methodenbuch Band III, Verband Deutscher Landwirtschaftlicher Untersuchungs Und Forschungsanstalten (VDLUFA), VDLUFA, Darmstadt, Germany, 3rd edition, 1997.
[14] E. Middleton Jr., C. Kandaswami, and T. C. Theoharides, “The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer,” Pharmacological Reviews, vol. 52, no. 4, pp. 673–751, 2000.
[15] B. A. Graf, P. E. Milbury, and J. B. Blumberg, “Flavonols, flavones, flavanones, and human health: epidemiological evidence,” Journal of Medicinal Food, vol. 8, no. 3, pp. 281–290, 2005.
[16] J. Barnes, “Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: efficacy and safety,” British Journal of Clinical Pharmacology, vol. 55, no. 4, pp. 331–340, 2003.
[17] J. Barnes, “Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality,” British Journal of Clinical Pharmacology, vol. 55, no. 3, pp. 226–233, 2003.
[18] E. Middleton, “Biological properties of plant flavonoids: an overview,” International Journal of Pharmacognosy, vol. 34, no. 5, pp. 344–348, 1996.
[19] L. G. Miller, “Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions,” Archives of Internal Medicine, vol. 158, no. 20, pp. 2200–2211, 1998.
[20] S. Lesser and S. Wolffram, “Oral bioavailability of the flavonol quercetin—a review,” Current Topics in Nutraceutical Research, vol. 4, no. 3-4, pp. 239–256, 2006.
[21] B. A. Graf, W. Mullen, S. T. Caldwell et al., “Disposition and metabolism of [2-14C]quercetin-4’-glucose in rats,” Drug Metabolism and Disposition, vol. 33, no. 7, pp. 1036–1043, 2005.
[22] P. Ader, A. Wessmann, and S. Wolffram, “Bioavailability and metabolism of the flavonol quercetin in the pig,” Free Radical Biology and Medicine, vol. 28, no. 7, pp. 1056–1067, 2000.
[23] E. U. Graefe, J. Wittig, S. Mueller et al., “Pharmacokinetics and bioavailability of quercetin glycosides in humans,” Journal of Clinical Pharmacology, vol. 41, no. 5, pp. 492–499, 2001.
[24] M. Reinboth, S. Wolffram, G. Abraham, F. R. Ungemach, and R. Cermak, “Oral bioavailability of quercetin from different quercetin glycosides in dogs,” British Journal of Nutrition, vol. 104, no. 2, pp. 198–203, 2010.
[25] S. Wein and S. Wolffram, “Oral bioavailability of quercetin in horses,” Journal of Equine Veterinary Science, vol. 33, pp. 441–445, 2013.

[26] L. H. Cazarolli, L. Zanatta, E. H. Alberton et al., “Flavonoids: prospective drug candidates,” Mini Reviews in Medicinal Chemistry, vol. 8, no. 13, pp. 1429–1440, 2008.

[27] J.-H. Kim, M.-J. Kang, H.-N. Choi, S.-M. Jeong, Y.-M. Lee, and J.-I. Kim, “Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus,” Nutrition Research and Practice, vol. 5, no. 2, pp. 107–111, 2011.

[28] Y. Q. Li, F. C. Zhou, F. Gao, J. S. Bian, and F. Shan, “Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of α-glucosidase,” Journal of Agricultural and Food Chemistry, vol. 57, no. 24, pp. 11463–11468, 2009.

[29] H.-W. M. Breuer, “Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes,” International Journal of Clinical Pharmacology and Therapeutics, vol. 41, no. 10, pp. 421–440, 2003.

[30] G. L. Kellett, E. Brot-Laroche, O. J. Mace, and A. Leturque, “Sugar absorption in the intestine: the role of GLUT2,” Annual Review of Nutrition, vol. 28, pp. 35–54, 2008.

[31] R. Cermak, S. Landgraf, and S. Wolffram, “Quercetin glucosides inhibit glucose uptake into brush-border-membrane vesicles of porcine jejunum,” British Journal of Nutrition, vol. 91, no. 6, pp. 849–855, 2004.

[32] J. Song, O. Kwon, S. Chen et al., “Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isofrom 2 (GLUT2), intestinal transporters for vitamin C and glucose,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 15252–15260, 2002.

[33] C. H. Baggio, C. S. Freitas, B. Mayer et al., “Muscarinic-dependent inhibition of gastric emptying and intestinal motility by fractions of Maytenus ilicifolia Mart ex. Reissek,” Journal of Ethnopharmacology, vol. 123, no. 3, pp. 385–391, 2009.

[34] I. E. Chazova and B. B. Mychka, “Metabolic syndrome treatment: focusing on acarbose,” Cardiovascular Therapy and Prevention, vol. 7, pp. 60–64, 2008.

[35] D. Brewer, “Are alpha-glucosidase inhibitors effective for control of type 2 diabetes?” American Family Physician, vol. 73, no. 3, pp. 433–3, 2006.

[36] G. Derosa and P. Maffioli, “Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review,” Clinical Therapeutics, vol. 34, pp. 1221–1236, 2012.

[37] A. Jenney, J. Proietto, K. O’Dea, A. Nankervis, K. Traianedes, and H. D’Embehn, “Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity,” Diabetes Care, vol. 16, no. 2, pp. 499–502, 1993.

[38] S. Okada, K. Ishii, S. Tanokuchi, H. Hamada, K. Ichiki, and Z. Ota, “Effect of α-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus,” Journal of International Medical Research, vol. 23, no. 6, pp. 492–496, 1995.

[39] S. Wein, N. Behm, R. K. Petersen, K. Kristiansen, and S. Wolffram, “Quercetin enhances adiponectin secretion by a PPAR-γ independent mechanism,” European Journal of Pharmaceutical Sciences, vol. 41, no. 1, pp. 16–22, 2010.

[40] S.-H. Bok, S.-Y. Park, B. P. Yong et al., “Quercetin dihydrate and gallate supplements lower plasma and hepatic lipids and change activities of hepatic antioxidant enzymes in high cholesterol-fed rats,” International Journal for Vitamin and Nutrition Research, vol. 72, no. 3, pp. 161–169, 2002.

[41] N. K. Gabler, E. Ostrowska, S. J. Sterling et al., “Consumption of raw brown onions variably modulate plasma lipid profile and lipoprotein oxidation in pigs fed a high-fat diet,” Journal of the Science of Food and Agriculture, vol. 85, no. 1, pp. 154–160, 2005.

[42] M. Pfeuffer, A. Auinger, U. Bley et al., “Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammatory parameters in men with different APOE isoforms,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, pp. 403–409, 2013.

[43] T. Sergent, J. Vanderstraeten, J. Winand, P. Beguin, and Y. J. Schneider, “Phenolic compounds and plant extracts as potential natural anti-obesity substances,” Food Chemistry, vol. 135, pp. 68–73, 2012.